Literature DB >> 17328067

Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients.

DeRen Huang1, Michael Cossoy, Meizhang Li, Dean Choi, Alan Taege, Susan M Staugaitis, Susan Rehm, Richard M Ransohoff.   

Abstract

OBJECTIVE: Inflammatory progressive multifocal leukoencephalopathy (iPML) with enhancing magnetic resonance imaging (MRI) lesions and leukocyte infiltration occurs in human immunodeficiency virus (HIV)-infected individuals after highly active antiretroviral therapy (HAART) treatment. MRI diagnostic criteria for PML suggest that iPML does not occur in HIV-negative individuals.
METHODS: We studied pathologically proved PML (12 by biopsy, 9 with MRI, 32 at autopsy).
RESULTS: HIV-negative (2/5) and -positive (2/4) PML patients had enhancing MRI lesions, correlated with CD3(+) lymphocyte infiltration. Inflammatory infiltrates occurred in the majority of HIV-negative (7/8) and HIV-positive/HAART (17/20) cases (p > 0.2), but in only 2 of 16 HIV-positive/non-HAART cases (p < 0.001).
INTERPRETATION: iPML showed radiographic and pathological similarity in HIV-positive/HAART and HIV-negative patients. HIV-negative iPML necessitates further consideration of MRI criteria for PML.

Entities:  

Mesh:

Year:  2007        PMID: 17328067     DOI: 10.1002/ana.21085

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

Review 2.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 4.  [Demyelinating disorders].

Authors:  T Weber; W Köhler
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 5.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 6.  Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review.

Authors:  Hayden Schwenk; Lynn Ramirez-Avila; Shu-Hsien Sheu; Christian Wuthrich; Jeff Waugh; Adam Was; Umberto Degirolami; Sandra Burchett; Igor J Koralnik; Asim Ahmed
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

Review 7.  CNS Infections in Immunoincompetent Patients : Neuroradiological and Clinical Features.

Authors:  Stefan Weidauer; Marlies Wagner; Simon Jonas Enkirch; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2019-09-19       Impact factor: 3.649

8.  Progressive multifocal leukoencephalopathy in non-HIV patient.

Authors:  Diego Rosseman Vieira; Diogo Zanella; Eurípedes Barsanulfo de Paula Avelino; Renato Batista Soares Moura; Gislaine Cristina Lopes Machado Porto; Liao Shin Yu; Rubens Chojniak
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

Review 9.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

Review 10.  Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.

Authors:  Elizabeth A Hartman; DeRen Huang
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.